OptiNose

OptiNose — Investor Presentation (March 2022)

30 slides from OptiNose's investor presentation, Mar 14, 2022

  1. Slide 1: Building a Leading ENT / Allergy Specialty Company

    Building a Leading ENT / Allergy Specialty Company Co r p o r a t e P r e s e n t a t i o n Ma r c h 1 4 , 2 0 2 2

  2. Slide 2: Forward-Looking Statements

    2 Forward‐Looking Statements This presentation and our accompanying remarks contain “forward‐looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward‐looking statements for this

  3. Slide 3: Our Growth Strategy

    3 Our Growth Strategy  Continue to commercialize XHANCE in the ENT and allergy specialty segments in the U.S.  Continue clinical development of XHANCE for the treatment of chronic sinusitis and expansion into the primary care segment to broaden our market opportunity  Seek additional development

  4. Slide 4: Our Pipeline

    Our Pipeline Basalt | chin | Pisses | ose2 | ruaea | non | ae (Nasal Polyps) XHANCE (Chronic Sinusitis) | rwnertrarms | chy | rsset | rimez | mes | non | Approwss ONZETRA® XSAIL® (Migraine) Licensed to Currax Orexia a Centessa Company (Orexin Agonists) 4 optinose_

  5. Slide 5: Commercializing XHANCE as a Treatment for Nasal Polyps

    Commercializing XHANCE® (fluticasone propionate) as a Treatment for Nasal Polyps

  6. Slide 6: Annual XHANCE Net Revenue Increases of More Than 50% in 2020 and 2021

    6 We Delivered Annual XHANCE Net Revenue Increases of More Than 50% in 2020 and 2021 With Our Commercial Model $30.4 $48.4 $73.7 2019 2020 2021 ($M ) XHANCE Net Revenues +52% +59%  We have a sales force of approximately 100 territory managers who target over 10,000 ENT and allergy specialists and "

  7. Slide 7: Strong New and Total Prescription Growth in 2020 and 2021

    7 153.7 261.4 335.6 2019 2020 2021 We Delivered Strong New and Total Prescription Growth in 2020 and 2021 During a Challenging Period for the INS Market +28% +70% 67.4 88.6 112.7 2019 2020 2021 XHANCE NRx (in thousands) +27% +31% XHANCE TRx (in thousands) NRx for Intranasal Steroids Market decreased

  8. Slide 8: XHANCE Market Share & Prescribers by Prescribing Frequency

    8 XHANCE Market Share & Prescribers by Prescribing Frequency The Market on this slide is defined as the sum of all intranasal steroid prescriptions written by physicians in the XHANCE target physician audience of approximately 18,000 physicians. Estimated based on monthly prescription data from thir

  9. Slide 9: Potential Value of a Chronic Sinusitis Indication

    Potential Value of a Chronic Sinusitis Indication

  10. Slide 10: What is Chronic Sinusitis (CS)

    10 What is Chronic Sinusitis (CS) CS is an inflammatory disease of the paranasal sinuses that is defined by the presence of at least two out of four cardinal symptoms (i.e., facial pain/pressure, hyposmia/anosmia, nasal drainage, and nasal obstruction) for at least 12 consecutive weeks, in addition

  11. Slide 11: First FDA-approved Drug Treatment for Chronic Sinusitis Creates New Growth Opportunities

    11 Successful Development of XHANCE as the First FDA‐approved Drug Treatment for Chronic Sinusitis Creates Multiple New Opportunities for Growth Up to approximately 1 Million patients with nasal polyps (NP) are treated by specialty physicians who are the current focus of our sales deployment 1 Milli

  12. Slide 12: CS Treatment Would Increase Opportunity and Address Barriers to Prescribing

    12 Successful Development of XHANCE as a Treatment for Chronic Sinusitis Would Increase Opportunity and Address Certain Barriers to Broader Prescribing that Exist Today Insurance  Today, ~80% of commercial lives are in plans that cover XHANCE, but ~half require physicians to attest that they are pr

  13. Slide 13: Our Chronic Sinusitis Development Program

    Our Chronic Sinusitis Development Program

  14. Slide 14: ReOpen1 and ReOpen2 Trial Design Summary

    14 EDS Placebo 372 μg Week 24 Double Blinded Phase En d of St ud y ReOpen1 and ReOpen2 Trial Design Summary Randomized, double‐blind, EDS‐placebo‐controlled, parallel‐group, multicenter studies to evaluate efficacy and safety of XHANCE 186 μg (1 spray) and 372 μg (2 sprays) BID in subjects with CS W

  15. Slide 15: ReOpen1 Phase 3 Trial: Design and Top-Line Results

    ReOpen1 A Landmark Phase 3 Trial in the Treatment of Chronic Sinusitis: Design and Top‐Line Results

  16. Slide 16: ReOpen1: Disposition and Baseline Characteristics

    16 Re‐Open 1: Disposition and Baseline Characteristics EDS Placebo XHANCE 186 mcg XHANCE 372 mcg Subjects Randomized 112 111 109 Subjects Who Completed Study 96 102 101 Subjects Discontinuing Early* 16 9 8 Full Analysis Set 110 110 107 Evaluable subjects with NP 69 69 67 Evaluable subjects without N

  17. Slide 17: ReOpen1: Combined Symptom Score Coprimary Endpoint

    17 ReOpen‐1: Combined Symptom Score Coprimary Endpoint 1 ‐0.62 ‐1.58‡ ‐1.60‡ ‐2.0 ‐1.8 ‐1.6 ‐1.4 ‐1.2 ‐1.0 ‐0.8 ‐0.6 ‐0.4 ‐0.2 0.0 CS S Po in t R ed uc tio n LS Mean Change in CSS from Baseline to Week 4 EDS‐placebo BID OPN‐375 186 μg BID OPN‐375 372 μg BID BID, twice daily; CSNS, composite symptom

  18. Slide 18: ReOpen1: Average Percent Opacified Volume Coprimary Endpoint

    18 ReOpen‐1: Average Percent Opacified Volume (Ethmoid and Maxillary) Objective CT scan Coprimary Endpoint ‐1.60 ‐5.58* ‐6.20* ‐7 ‐6 ‐5 ‐4 ‐3 ‐2 ‐1 0 Pe rc en t R ed uc tio n LS Mean Change in APOV of the Ethmoid and Maxillary Sinuses from Baseline to Week 24 EDS‐placebo BID OPN‐375 186 μg BID OPN‐3

  19. Slide 19: Illustration of APOV Improvement (186 µg BID)

    19 Illustration of APOV Improvement (Patient Receiving XHANCE 186 µg BID) 6.4% Improvement Week 24Baseline Images reflect individual results and results and may not be representative of results generally.

  20. Slide 20: Illustration of APOV Improvement (372 µg BID)

    20 Illustration of APOV Improvement (Patient Receiving XHANCE 372 µg BID) Week 24Baseline 7.0% Improvement Images reflect individual results and results and may not be representative of results generally.

  21. Slide 21: Secondary Endpoints and Subgroup Analysis

    21 Secondary Endpoints and Subgroup Analysis Top‐line results are limited: full analysis is still ongoing  Four defining symptoms of Chronic Sinusitis ‐ XHANCE‐ treated patients had statistically significant improvement over EDS‐placebo treated patients on each of the four symptoms (congestion, rhi

  22. Slide 22: AEs Occurring in ≥3% of Patients and More Common Than Placebo

    22 AEs Occurring in ≥3% of Patients and More Common Than Placebo Adverse Event (AE) EDS‐placebo BID (N =112) n (%) XHANCE 186 mcg BID (N =111) n (%) XHANCE 372 mcg BID (N =109) n (%) Epistaxis 1 (0.9) 5 (4.5) 13 (11.9) Nasopharyngitis 3 (2.7) 6 (5.4) 3 (2.8) Asthma 1 (0.9) 5 (4.5) 4 (3.7) Nuclear Ca

  23. Slide 23: Additional Phase 3b Clinical Trial Data Expected in Q2 22

    23 Additional Phase 3b Clinical Trial Data Expected in Q2 2022 Recruitment Completed July 2021 Recruitment Completed October 2021 Top‐line results presented in Q1 2022 Top‐line results expected in Q2 2022  ReOpen1 ClinicalTrials.gov Identifier: NCT03781804 Enrolled 332 patients with CS of which 205

  24. Slide 24: Additional Financial Information

    Additional Financial Information

  25. Slide 25: XHANCE Net Revenue per Prescription

    25 XHANCE Net Revenue per Prescription $198 $185 $219 2019 2020 2021 ($ ) XHANCE Net Revenue per Prescription  XHANCE net revenue per prescription ($/TRx) increased 11% from 2019 to 2021  In response to the COVID‐19 pandemic, Optinose offered the XHANCE ASSIST program in Q2 and Q3 2020  Commercia

  26. Slide 26: XHANCE Gross Margin and Consistent R&D plus SG&A Expense

    26 XHANCE Gross Margin Percentage and Consistent R&D plus SG&A Expense Has Enabled Revenue Growth to Translate to Decreasing Operating Loss ($000s) 2019 2020 2021 XHANCE Net Revenue 30,401 48,357 73,652 Licensing Revenues 4,230 750 1,000 Total Revenues 34,631 49,117 74,652 Cost of Product Sales 5,29

  27. Slide 27: Full Year 2022 Financial Guidance

    27 Full Year 2022 Financial Guidance  XHANCE Net Revenue ‒ Expected to be at least $90 million  XHANCE Average Net Revenue per Prescription ‒ FY 2022 expected to exceed $210  Operating Expense (GAAP) ‒ Expected to be between $135 – $140 million; approximately $10 million of which represents stock

  28. Slide 28: Investor Relations

    28 Investor Relations – NASDAQ: OPTN Optinose Investor Contact Jonathan Neely, VP, Investor Relations and Business Development 267‐521‐0531 [email protected] At 31 December 2021: – $111 million in cash – Long‐term debt: $130 million – 82.2 million common shares o/s – 12.4 million options, warra

  29. Slide 29: Building a Leading ENT / Allergy Specialty Company

    Building a Leading ENT / Allergy Specialty Company Co r p o r a t e P r e s e n t a t i o n Ma r c h 8 , 2 0 2 2

  30. Slide 30: Key Takeaways and Q4 2021 Highlights

    30 Key Takeaways and Q4 2021 Highlights Consistent Commercial Execution Driving Q4 2021 Growth FY 2022 Revenue Guidance Implies Y/Y Growth of at least 22% Positive Top‐Line Results from ReOpen1 Reported in 1Q2022 +44% XHANCE Net Revenue Growth Q4 2021/Q4 2020 $240 XHANCE Net Revenue per TRx in Q4 20

OptiNose — Investor Presentation (March 2022) on 6ix